Diminishing Returns from the Government’s Drug Negotiation Program
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the next 15 drugs that will be subject to government price negotiations.
House Committee Calls for CMS Action on Biosimilars
“‘One of the ways to align these incentives would be for CMS, in particular the Center for Medicare & Medicaid Innovation, to launch a demonstration project, a shared savings program in Medicare Part B for biosimilars. This would reward physicians for increasing their utilization of biosimilars, which would both create that incentive for physicians and align that incentive with the desire of taxpayers to lower overall costs in the biologic spend category,’ [Alex Brill] said.”
Observable Flaws in CMS’s Dialysis Star-Rating System and a Proposed Alternative
In January 2015, CMS launched a star-rating system for U.S. dialysis facilities. This article analyzes nearly 6,000 U.S. dialysis facilities and explores trends and variations in star-rating scores based on facility characteristics and local demographic factors. Statistical tests show variation across states and by demographic factors.
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
